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Abstract
Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion. 
While diagnostic and therapeutic methods have advanced, little information exists 
on trends in acromegaly characteristics over time. The Liège Acromegaly Survey (LAS) 
Database, a relational database, is designed to assess the profile of acromegaly patients 
at diagnosis and during long-term follow-up at multiple treatment centers. The 
following results were obtained at diagnosis. The study population consisted of 3173 
acromegaly patients from ten countries; 54.5% were female. Males were significantly 
younger at diagnosis than females (43.5 vs 46.4 years; P < 0.001). The median delay from 
first symptoms to diagnosis was 2 years longer in females (P = 0.015). Ages at diagnosis 
and first symptoms increased significantly over time (P < 0.001). Tumors were larger in 
males than females (P < 0.001); tumor size and invasion were inversely related to patient 
age (P < 0.001). Random GH at diagnosis correlated with nadir GH levels during OGTT 
(P < 0.001). GH was inversely related to age in both sexes (P < 0.001). Diabetes mellitus was 
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present in 27.5%, hypertension in 28.8%, sleep apnea syndrome in 25.5% and cardiac 
hypertrophy in 15.5%. Serious cardiovascular outcomes like stroke, heart failure and 
myocardial infarction were present in <5% at diagnosis. Erythrocyte levels were increased 
and correlated with IGF-1 values. Thyroid nodules were frequent (34.0%); 820 patients 
had colonoscopy at diagnosis and 13% had polyps. Osteoporosis was present at diagnosis 
in 12.3% and 0.6–4.4% had experienced a fracture. In conclusion, this study of >3100 
patients is the largest international acromegaly database and shows clinically relevant 
trends in the characteristics of acromegaly at diagnosis.
Introduction
Acromegaly is caused by chronic hypersecretion of 
growth hormone (GH) and insulin-like growth factor-1 
(IGF-1), usually due to a GH-secreting pituitary adenoma 
(somatotropinoma) (Melmed 2017). Acromegaly is a 
rare disorder; modern epidemiological data from various 
population-based (Daly et al. 2006, Fernandez et al. 2010) 
and insurance database studies (Burton et  al. 2016) are 
available and suggest that acromegaly has a prevalence 
of 2.8–13.7 cases/100,000 and an incidence of 0.2–1.1 
cases/100,000 (Lavrentaki et al. 2016).
Chronically elevated GH and insulin-like growth 
factor-1 (IGF-1) levels lead to a complex spectrum of 
signs that include acral overgrowth, facial changes, 
musculoskeletal disease or gigantism if the GH 
hypersecretion occurs before epiphyses have fused 
(Melmed 2017). Patients with active acromegaly also 
suffer from cardiovascular and metabolic abnormalities, 
including hypertension, arrhythmia, cardiomegaly, 
diabetes mellitus and dyslipidemia (Melmed et al. 2013). 
Together these lead to increased morbidity and mortality 
in acromegaly, predominantly due to cardiovascular and 
respiratory disease (Stewart & Sherlock 2012, Ritvonen 
et  al. 2015, Ramos-Leví & Marazuela 2017). Bringing 
GH/IGF-1 levels within the normal range returns 
mortality to that of the general population, although the 
precise threshold at which risk normalization occurs is 
debated (Holdaway et al. 2008, Sherlock et al. 2010).
Methods for the management of acromegaly have 
evolved over the past 40 years and for most approaches, 
the efficacy and safety profiles are well documented. 
Neurosurgical techniques have been refined from the 
first trans-sphenoidal operations to new endoscopic 
techniques, while medical therapies now involve a 
range of options from somatostatin analogs (SSA) and 
somatostatin receptor ligands (SRL) to the growth hormone 
(GH) receptor antagonist pegvisomant and dopamine 
agonists (Melmed 2016). Radiotherapy techniques have 
undergone significant developments leading to the 
gamma-knife used today. Modern acromegaly therapy is 
guided by recommendations from consensus publications, 
with primary neurosurgery potentially offering cure 
in pituitary tumors that are smaller or uncomplicated 
(Giustina et  al. 2010, Katznelson et  al. 2014). In many 
patients, multimodal therapy is needed, particularly for 
those with aggressive disease or non-resectable tumors.
As a rare disease, studies on acromegaly have generally 
focused on relatively small populations or have addressed 
regional or national cohorts and patients enrolled in 
treatment-specific safety databases (Jenkins et  al. 1995, 
Sherlock et al. 2009, Trainer 2009, Tritos et al. 2014). Data 
from such studies have provided valuable information 
about acromegaly and have contributed to improvements 
in patient management. Large international studies of 
the clinical characteristics and therapeutic evolution 
of unselected groups of acromegaly patients do not 
exist. We were interested in studying multiple aspects 
of acromegaly, including detailed assessments of large 
numbers of data points covering hormonal, pathological, 
genetic, clinical and therapeutic measures and how these 
factors are interrelated. We developed and deployed a 
relational database, the Liège Acromegaly Survey (LAS) 
Database, for the analysis of data collected from large 
populations of patients with acromegaly. Following 
preliminary studies to validate the data collection and 
analysis potential of the LAS Database (Theodoropoulou 
et al. 2009, Petrossians et al. 2012, Franck et al. 2017), we 
report the first comprehensive study of 3173 acromegaly 
in patients from 14 participating centers across Europe.
Methods
The study included patients with an established diagnosis of 
acromegaly at the 14 study centers across Belgium (Centre 
Hospitalier Universitaire de Liège), Bulgaria (Medical 
Endocrine-Related Cancer  
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University, Sofia), Czech Republic (Charles University, 
Prague), France (Paris Sud University, Le  Kremlin-Bicêtre; 
Hôpital de la Timone, Marseille, Centre Hospitalier 
Universitaire de Reims), Germany (Max Planck Institute of 
Psychiatry, Munich), Italy (Federico II University, Naples; 
University of Genoa, Genoa; University of L’Aquila; and 
Neuromed, Pozzilli), the Netherlands (Erasmus University 
Medical Center, Rotterdam), Portugal (Centro Hospitalar S. 
João, Porto), Spain (Hospital Universitario de la Ribera, Alzira) 
and Sweden (Karolinska University Hospital, Stockholm).
The LAS Database is a relational database that permits 
the analysis of comprehensive arrays of data covering 
laboratory values, dose adaptation of treatment and 
clinical evolution. The goal of the LAS Database was to 
design a framework to capture available data on >2000 
acromegaly patients and to permit statistically robust 
analysis of clinically relevant topics. The database 
management system was kept separate from the data 
capture interface. The open source mySQL server (Oracle, 
USA) was used to store the data, while the data capture 
interface used locally at each participating center was 
programmed using the Delphi RAD system. The initial 
development and validation of the framework is described 
in Petrossians and coworkers (Petrossians et al. 2012).
The current study ran from 30 September, 2012, to 
1  January, 2015, and data cutoff for this analysis was 
1 October, 2016. All patients with a diagnosis of acromegaly 
at the participating centers up to 1 January 2015 were 
valid for inclusion. Those with valid demographic data 
and at least one post-diagnosis/baseline follow-up 
dataset were included in the statistical analysis. There 
was no upper or lower limit to the duration of follow-up, 
number of treatments or treatment adaptations, drug 
dose alterations or hormonal/clinical/radiological results 
recorded over time. Complete data on the 147 variables 
that were collected over the course of the patient’s clinical 
follow-up were to be entered; when an assessment had 
not been performed (e.g. cardiac ultrasound, colonoscopy, 
polysomnography), these individuals were not included 
in the statistical analysis for that particular parameter. 
Hormonal data have evolved over time due to refinements 
in assay methodologies, which can lead to inconsistencies 
when comparing values. The LAS Database accounted for 
changes in GH assay reference ranges by automatically 
converting values in ng/mL to µU/mL based on the 
date and reference used in the center at that time. For 
IGF-1, absolute measured values were encoded along 
with the upper limit of normal for age and sex based on 
the assay used at the center. Results were then expressed 
as percent of upper limit of the normal value (%ULN). 
Radiological data for the maximal tumor diameter were 
used to calculate the proportion of patients with micro 
(<10 mm) and macroadenomas (≥10 mm) on MRI scans at 
diagnosis. Nodular thyroid disease was considered present 
when a solitary thyroid nodule or a multinodular goiter 
was confirmed on ultrasound. Diabetes was considered 
as being present when a diagnosis had been made in the 
medical history of the patient and/or a recorded glucose 
value of ≥200 mg/dL was found at 120 min during a 
standard oral glucose tolerance test (OGTT). Genetic 
studies were not performed specifically over the course of 
this study and only information on familial diseases or 
previously established genetic diagnoses was collected.
The study was performed under a central Ethics 
Committee approval covering all centers from the 
Centre Hospitalier Universitaire de Liège, while each 
individual center complied with their individual local 
ethics requirements and procedures. Data were encoded 
locally using the LAS Database data capture interface and 
each patient entered was assigned an anonymous study 
identifier. Patient identifying information was never 
shared with the central database where information from 
participating centers was pooled for analysis.
Statistics
To examine the evolution of factors over time the study 
population was divided by study center, gender and decade 
of diagnosis. Data were analyzed using the R software 
package (R Core Team 2015; http://www.R-project.org) 
and graphics were plotted using the Lattice package 
(Lattice, Sarkar D. New York (2008). For continuous 
variables, data were plotted and tested for normality. As 
none of the variables had a normal distribution, data were 
expressed as median and interquartile range (IQR) from 
the first to the third quartile (25th and 75th percentiles). 
Data distribution was represented graphically with 
density graphs using Gaussian kernel smoothing with 
individual data points plotted at the abscissa (‘rug’). Data 
spreads were drawn using boxplots showing the medians 
and interquartile ranges, while the whiskers represented 
1.5 times the interquartile ranges. Statistical comparisons 
were performed using the Mann–Whitney test. Single 
and multiple regression analyses were performed using 
generalized additive models. Count variables were 
compared using the χ2 test. Time data were analyzed 
either continuously for regression models or divided into 
four groups (before 1990, 1990–1999, 2000–2009, 2010 
and after). The earliest date (pre/post 1990) was chosen 
as it represents a period when new diagnostic (MRI) 
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Figure 1
(A) Dot plot showing the sex ratio (M/F) and the number (n) of patients in the LAS Database and for individual centers. Centers were sorted based on the 
sex ratio, in decreasing order. (B) Median age of patients at diagnosis represented as separate boxplots for males and females. Centers were sorted based 
on the median age of diagnosis of all patients for each center (values in parenthesis). (C) Evolution of median age at diagnosis over time. (D) Estimated 
delay between the first symptoms of acromegaly as reported by patients and the diagnosis of acromegaly, and displayed by the decade of diagnosis. 
(E) Proportions of LAS Database patients diagnosed by different medical (generalist, specialist) or health care workers and non-medical individuals.
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and therapeutic (somatostatin analogs) modalities 
were becoming generally available. Patient ages were 
also analyzed either as continuous values for regression 
and Mann–Whitney tests or grouped into categories: 
0–29 years, 30–49 years, 50–64 years and ≥65 years.
Results
Study population and demographics
The study population consisted of 3173 patients with 
a diagnosis of acromegaly. There was a slight female 
predominance (F = 1729; 54.5%) across the total 
population, and this tended to decrease over time from 
57.3% in those diagnosed before 1990 to 50.6% of those 
diagnosed after 2010. The male-to-female ratio (0.84) 
varied across the centers from 0.43 to 1.4 (Fig. 1A and B). 
A total of 468 cases underwent 777 genetic tests related 
to acromegaly; 73 patients had known genetic/inherited 
or syndromic features, 28 had an AIP gene mutation, 13 
were from other AIP-negative familial isolated pituitary 
adenomas (FIPA) kindreds, 11 had McCune Albright 
syndrome, seven had multiple endocrine neoplasia type 
1 (MEN1) and two had Carney complex. Five patients 
had acromegaly secondary to ectopic growth hormone-
releasing hormone (GHRH) secreting tumors.
The median age of diagnosis was 45.2  years 
(IQR: 34.9–55.0  years) and was significantly younger in 
males (43.5 years (IQR: 34.2–53.1)) than that in females 
(46.4  years (IQR: 35.6–56.1); P < 0.001). The median 
age at first symptoms of acromegaly was 33.5  years 
(IQR: 23.6–44.5  years) overall and did not differ 
significantly between the sexes. The median delay in 
diagnosis was, however, significantly longer for females 
(10 years (IQR: 4.0–18.0)) as compared with males (8 years 
(IQR: 4.0–15.0); P = 0.015). The age at diagnosis increased 
over time in both sexes, with those in the most recent 
group (post-2010) being nearly 7 years older than the pre-
1990 group (48.79 (39.3–58.9) vs 41.8 (32.5–52) P < 0.001; 
Fig. 1C). The median age at first symptoms of acromegaly 
(as recalled by the patient) also increased over time with 
patients diagnosed in the current decade being 17.1 years 
older than those diagnosed pre-1990 (41.7 (32.6–50.5) 
vs 24.6 (14–33.8); P < 0.001). Over time, however, 
acromegaly was associated with a shorter delay between 
first symptoms and diagnosis (Fig. 1D).
Acromegaly was most frequently diagnosed by 
endocrinologists (44.9%), general/family practitioners 
(17.5%) or internists (13.2%). Other diagnostic settings 
included rheumatologists/orthopedic specialists (3.6%), 
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(A) Density plot and box plot representing the maximal diameter of 
tumor at diagnosis. Data for the whole population (black line), male 
(blue line) and female patients (red line) are shown. Individual patients 
are represented below the density plot (‘rug’). (B) Maximal tumor 
diameter in groups of patients based on the age at diagnosis. (C) Age of 
patients at diagnosis in those with micro/macro adenomas and in those 
with tumor invasion.
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neurologists (3.3%) and ophthalmologists (2.3%), while 
in 2.3% of cases, the diagnosis was made by the patient 
themself or their family/friends (Fig. 1E). The most frequent 
signs/symptoms leading to presentation with acromegaly 
were changes in physical appearance, with 21.5% reporting 
dysmorphic features and 13.6% enlarged extremities. Other 
presenting signs included headache (7.5%), fatigue/asthenia 
(5.9%), sweating (2.0%) and sleep apnea (1.0%). In 8.4% of 
female patients, menstrual disturbances were among the 
symptoms leading to presentation with acromegaly.
Radiological characteristics
At diagnosis, pituitary imaging data were available in 2545 
cases, of which 1691 had an MRI and 854 had a CT scan. 
The median tumor size at diagnosis was 15 mm (Fig. 2A) 
and 71.8% of cases had a macroadenoma. In 4.6% of 
cases, no pituitary tumor was visualized. Males had 
larger tumors at diagnosis than females (P < 0.001), while 
tumor size at diagnosis was inversely related to patient 
age (Fig. 2B). Hence, patients with macroadenomas were 
significantly younger (P < 0.001; Fig.  2C) and had more 
frequent cavernous sinus invasion at diagnosis (P < 0.001). 
The difference in tumor size between males and females 
was due to patients under 30  years of age at diagnosis 
(P = 0.002) as there was no significant difference between 
the sexes in tumor size in older patients (data not shown). 
In keeping with larger tumor size, younger patients had a 
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(A) GH levels in groups of patients based on the age at diagnosis. (B) 
Scatterplot of GH levels at diagnosis vs maximal tumor diameter. The 
dotted line is the linear regression between these two variables, whereas 
the continuous line is the result of a loess (locally weighted least squares 
regression) smoothing. The latter shows the lack of a correlation 
between tumor size and GH secretion for larger tumors. (C) Scatterplot 
and regression line between GH nadir concentration during OGTT vs 
random GH measurement.
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Figure 4
Age of male and female patients at diagnosis based on prolactin (PRL) 
co-secretion by the adenoma.
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higher rate of chiasmal compression at diagnosis, which 
was 23.0% in those aged <30  years but only 10.0% in 
those aged >65 years at diagnosis; this was present in both 
sexes (P < 0.001). The proportions of patients with micro/
macroadenomas did not change over time. Invasion was 
present in 47.6% of tumors at baseline (Fig. 2C); there was 
no difference between the sexes and no change was seen 
in the percentage of cases with invasion over time.
Hormonal profiles
At each age group studied, there was no difference between 
males and females in terms of GH level at diagnosis. GH 
levels at diagnosis were inversely related to patient age in 
both sexes (P < 0.001; Fig. 3A). A linear regression analysis 
between GH at diagnosis and maximal tumor diameter at 
diagnosis showed an increase of GH values with the size 
of tumor, but only up to a maximum tumor diameter of 
20 mm; thereafter, no correlation with GH values existed 
(Fig. 3B). Random GH at diagnosis correlated closely with 
nadir GH levels during OGTT (P < 0.001, Fig.  3C). Over 
time, GH levels at diagnosis fell significantly; this was 
mainly driven by lower GH at diagnosis among females 
over time from pre-1990 to the current decade (P < 0001). 
As there was also a weak association between the date of 
diagnosis and the GH level, it cannot be excluded that 
changes in assay ranges could also contribute to this 
finding.
IGF-1 levels (%ULN) were higher at diagnosis 
among younger acromegaly patients; this difference was 
significant for the study population overall and male 
patients but not females (P < 0.001). IGF-1 (%ULN) also 
correlated with tumor size (P = 0.04). Prolactin co-secretion 
occurred in 10% of cases, while among surgically operated 
patients, mixed GH/PRL staining was described in 26.3% 
of tumors. Patients with prolactin co-secretion were 
significantly younger at diagnosis than other acromegaly 
patients (Fig.  4). Additionally, patients with GH and 
prolactin co-secretion had significantly larger tumors 
(P < 0.001) that were more likely to be invasive at diagnosis 
than other patients. Co-secretion of hormones other than 
prolactin was rarely seen at diagnosis (ACTH: 0.41%, TSH: 
0.16%, gonadotropins: 0.13%).
Comorbidities at diagnosis
Metabolic system
At diagnosis of acromegaly, 24.5% of patients had type 2 
diabetes, while three individuals had type 1 diabetes. In 
addition, when 120-min glucose values on OGTT were 
assessed, a further 24 patients not previously diagnosed 
with diabetes had glucose values >200 mg/dL at 120 min. 
Including all these patients, the prevalence of diabetes 
mellitus at diagnosis in acromegaly patients was 27.5%. 
In non-diabetic patients, glucose values (basal or at OGTT) 
did not correlate with GH levels (P = 0.19; Fig. 5A and B). 
Glucose levels did, however, correlate significantly with 
IGF-1 values when expressed in absolute terms (P < 0.01) and 
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Figure 5
Scatter plots and regression lines of basal glucose (A) and glucose at 
120 min during OGTT (B) vs GH levels in non-diabetic patients.
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as %ULN (P = 0.038; Fig. 6A, B, C and D). The median total 
cholesterol level was 183.2 mg/dL (IQR: 134.0–216.2 mg/dL). 
Total cholesterol levels were higher in females than those 
in males at diagnosis: 189.0 mg/dL (IQR: 139.9–221.4) vs 
178.0 mg/dL (IQR: 133.0–205.0). Males were nearly twice 
as likely to be current smokers as females at the time of 
diagnosis (22.1 vs 11.9%, respectively).
Cardiovascular system
As cardiovascular disease is an important cause of 
morbidity/mortality in acromegaly, we were interested 
in determining the prevalence of important variables 
at diagnosis, in addition to diabetes and lipid profiles 
described previously. Among these, hypertension was the 
most frequent, occurring in 28.8% of patients overall at 
diagnosis, and this remained relatively constant across 
time of inclusion into the study. Cardiac hypertrophy 
was reported in 15.5% of patients at diagnosis. Other 
important cardiovascular morbidities were less frequent 
at diagnosis: stroke (4.5%), arrhythmia (3.6%), ischemic 
heart disease (3.5%), myocardial infarction (3.0%) and 
heart failure (1.6%). Patients with hypertension, cardiac 
hypertrophy, cardiac failure, ischemic heart disease 
IGF−1 (ng/ml)
A B
C D
G
lu
co
se
 (m
g/
dL
)
50
100
150
0 500 1000 1500 2000
IGF−1 (ng/ml)
G
lu
co
se
 a
t 1
20
 m
n 
du
rin
g 
O
G
TT
 (m
f/d
L)
50
100
150
0 500 1000 1500 2000
IGF−1 (%)
G
lu
co
se
 (m
g/
dL
)
50
100
150
200 400 600 800 1000
IGF−1 (%)
G
lu
co
se
 a
t 1
20
 m
n 
du
rin
g 
O
G
TT
 (m
g/
dL
)
50
100
150
200 400 600
Figure 6
Scatter plots and regression lines of glucose vs IGF-1 levels in non-diabetic patients. (A) Basal glucose vs measured IGF-1. (B) Glucose at 120 min during 
OGTT vs measured IGF-1. (C) Basal glucose vs IGF-1 expressed as a percentage of the upper limit of normal (% ULN). (D) Glucose at 120 min during OGTT 
vs IGF-1 expressed as % of ULN.
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and arrhythmia at diagnosis were all significantly older 
at diagnosis than those without these cardiovascular 
comorbidities (P < 0.001). Sleep apnea syndrome had 
been diagnosed in 25.5% of the cohort. In centers 
where polysomnography was systematically performed, 
sleep apnea syndrome was detected in 69.0% of 
tested subjects.
Red blood cell counts (analyzed separately for males 
and females) did not show any correlation with random 
GH or GH nadir during OGTT (P = 0.46), but RBC count 
increased with absolute IGF-1 values (P = 0.046) and %ULN 
values (P < 0.001). Similarly, hemoglobin concentration 
was not correlated with GH levels but was positively 
correlated with absolute IGF-1 values (P = 0.017) and IGF1 
%ULN (P < 0.001).
Other comorbidities
Overall, 34.0% of patients had a thyroid nodule or goiter 
reported at diagnosis. There was no relationship between 
other demographic or hormonal factors and the presence 
of thyroid nodules. At diagnosis, 13% of patients who 
had a colonoscopy (n = 820) had colonic polyps identified. 
There was no difference in GH and IGF-1 levels between 
patients with and without polyps. Four patients had 
been diagnosed with colorectal cancer at diagnosis. In 
total, 64 patients had a diagnosis of cancer, the most 
common of which were breast (n = 16), thyroid (n = 11) 
and skin (n = 10). At diagnosis, 12.3% of patients had been 
diagnosed with osteoporosis. A hip fracture had occurred 
by the time of diagnosis in 4.4% of acromegaly patients, 
whereas 4.3% had suffered a vertebral fracture and 0.6% 
a wrist fracture. There was only a significant relationship 
between age at diagnosis and the presence of any fracture 
in female patients (P = 0.012).
Discussion
Acromegaly is a rare endocrine disorder that is due to 
chronic GH hypersecretion, usually from a pituitary 
adenoma. It is usually diagnosed and managed in 
expert referral centers, but due to its rarity even 
pituitary specialists might see only a couple of hundred 
cases over their full careers. One way to improve our 
understanding of rare disorders is by pooling data from 
many centers using patient registries. In acromegaly, 
this has been done extensively on a regional and 
national basis in Europe and Mexico (Jenkins et al. 1995, 
Mestron et al. 2004, Reincke et al. 2006, Bex et al. 2007, 
Portocarrero-Ortiz et  al. 2016, Maione et  al. 2017). 
Commercial entities support clinical databases to detect 
and report on the safety of medical therapies, such as, 
the pegvisomant ACROSTUDY program (van der Lely 
et al. 2012, Freda et al. 2015, Bernabeu et al. 2016). The 
data obtained from these registries have stimulated 
ideas on aspects of morbidity, hormonal control and 
medical treatment patterns that have later been proven 
in independent clinical trials. National registries do 
have limitations in terms of patient numbers and 
the applicability of data to treatment norms in other 
countries. International acromegaly databases with a 
common underlying data capture methodology have 
been long called for (Stewart 2004).
The LAS Database was originally developed and validated 
as a single-center study tool (Petrossians et al. 2012), and 
thereafter, was expanded across multiple European centers 
in the current study; it has been used successfully to 
facilitate analyses of disease characteristics and treatment 
responses in various centers (Theodoropoulou et al. 2009, 
Franck et  al. 2017). The LAS Database provides some 
specific advantages in that it is not limited to a national 
dataset nor does it deal with patients managed with a single 
treatment modality. The programming of the LAS Database 
is a relational database that permits integrated statistical 
analyses of independent variables, which is a challenge 
for other registry-based listing. The LAS Database variables 
(nearly 150 in total)were chosen based on extensive input 
from acromegaly specialists in order to permit clinically 
relevant questions and changes in criteria over time to be 
addressed with robust statistical methods.
In the cohort, there was a small female predominance 
overall (54.5%), which is in keeping with results from 
other national centers in Europe and elsewhere (Sesmilo 
et  al. 2012, Portocarrero-Ortiz et  al. 2016, Lesén et  al. 
2017, Maione et  al. 2017). Over time, though, the sex 
prevalence changed, such that those patients diagnosed 
post-2010 were nearly evenly balanced (M:F 49.4%: 
50.6%). Acromegaly usually has an occult onset and a 
long period of symptoms can occur before a diagnosis is 
made. In a two-center study in the United States, Reid and 
coworkers suggested that delayed diagnosis contributed 
to acromegaly patients presenting with similar disease 
characteristics over the period 1981–2006 (Reid et  al. 
2010). In the LAS Database, first symptoms were seen in 
the mid-30s in both sexes. However, it took significantly 
longer (2  years) for females to achieve a diagnosis than 
males, which is clinically relevant and indicates improved 
awareness of acromegaly in women is needed. As the delay 
between first symptoms and diagnosis decreased over 
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the course of the study, this suggests that the efficiency 
of referral and diagnosis is improving. This may be due to 
much wider access to MRI and other specialist techniques 
and better emphasis on concentrating pituitary expertise 
in regional referral centers; improved awareness of 
acromegaly may itself play a part in decreasing the delay 
before diagnosis. It is interesting to note that the age at 
diagnosis in the cohort overall increased by nearly seven 
years from 1990 to the current decade. It has long been 
noted that older patients with acromegaly can have milder 
disease features and hormonal abnormalities (van der Lely 
et al. 1992). More recently, it has been noted that a group 
of patients with ‘normal’ GH and elevated IGF-1 exists, 
that are older and have smaller tumors than acromegaly 
patients with typically raised GH and IGF-1 parameters 
(Dimaraki et al. 2002, Butz et al. 2016). It may be that the 
wider access to MRI and greater awareness noted above is 
also leading to increased pick-up of a milder phenotype 
of acromegaly in an older population. In support of this, 
hormonal data from the current cohort show a fall in GH 
at diagnosis over time, due mainly to female acromegaly 
patients. The correlations between patient age, tumor size 
and GH secretion suggest an apparent triangular relation 
among these three variables. The later the age at diagnosis, 
the smaller the tumors and the lower the diagnostic GH 
values; the reverse situation was also true. This raises 
different possible interpretations. Is milder disease simply 
being overlooked in younger patients or are older patients 
more sensitive to small increases in GH secretion? It is 
more likely, however, that acromegaly is heterogeneous, 
and there are distinct phenotypes that can be identified. 
A number of pathological features might explain this 
difference, including genetic causes, such as AIP mutations 
that predominately affect younger males (Daly et al. 2010). 
Over representation of AIP-mutated cases among younger 
subgroups of the current cohort could have influenced 
the tumor size characteristics. As only a minority of 
patients underwent tumoral or germline genotyping, this 
hypothesis remains speculative. GH values at diagnosis 
decreased with patient age and increased with tumor 
size, although this later linear relation was not present for 
tumors measuring more than 20 mm in diameter. This may 
be explained by tumoral necrosis in bigger tumors or by 
two different populations of tumors with the bigger tumors 
being aggressive tumors secreting relatively low levels of 
GH that appear as hyper-intense lesions on T2-weighted 
MRI sequences (Potorac et al. 2015, 2016). Further studies 
comparing T2 imaging signal, histologic features and 
tumoral secretion may shed more light on this observation.
Improvements in diagnosis of acromegaly can come 
from greater awareness among those who first see the 
patient. In the LAS Database cohort, the initial diagnosis 
of acromegaly was made by an endocrinologist in nearly 
45% of cases. As shown in Fig.  1, the variety of non-
endocrine specialists that make acromegaly diagnoses 
is quite marked. Given the range of potential signs/
symptoms and the specific problems caused by a pituitary 
adenoma, it is crucial that awareness of pituitary tumors 
continues to be widened across medical specialties and 
related groups (Surchi et  al. 2017). Delays in diagnosis 
in patients that attend with multiple symptoms of 
acromegaly still occur as illustrated clearly by De and 
Foucault, leading to unnecessary exposure of excessive 
GH/IGF-1 (De & Foucault 2014). Interestingly, in the age 
of widespread Internet searching related to medicine, 
as many people or friends/family diagnosed himself 
or herself with acromegaly as did ophthalmologists. 
Improved understanding of the pattern of signs and 
symptoms suggestive of acromegaly is still needed among 
both the health care sector and the general public.
Studies in acromegaly routinely use random GH 
measurements, whereas the nadir of GH during OGTT 
is considered as the ‘gold standard’ of GH assessment. 
In this cohort of >3100 patients, a linear regression 
between nadir GH and random GH showed a good 
correlation between these two measures suggesting that 
using random measurement of GH is a clinically valid 
practice, as suggested by others (Bajuk Studen & Barkan 
2008). Despite extensive clinical research, the question 
still arises as to which hormonal measurement, GH or 
IGF-1 (or both), is the best representation of the activity 
of acromegaly. Indeed in clinical practice, patients 
with high levels of GH and comparatively low (albeit 
elevated) levels of IGF-1 are seen, contrasting with other 
patients with slightly increased or normal levels of GH 
but markedly elevated levels of IGF-1. Which of these 
patients should be considered as being the most exposed 
to active acromegaly? One pointer may come from 
comparing other biological markers like glucose. Detailed 
study of acromegaly patients with diabetes is limited since 
these patients are already receiving treatment, and they 
may show different compliance toward their diet and 
therapy. Therefore, we assessed the effect of hormonal 
secretion in non-diabetic patients. Glucose levels in 
acromegaly patients increased with rising levels of IGF-
1, whereas no correlation was found with GH. Although 
GH induces insulin resistance and raises glucose, in the 
clinical setting, IGF-1 may represent a better marker of the 
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metabolic burden of acromegaly; this point is echoed in 
other national cohort analyses (Alexopoulou et al. 2008).
Acromegaly is associated with increased mortality 
when hormonal levels are not controlled (Dekkers 
et  al. 2008). The presence of important comorbidities 
contributes to this and the range of pathologies seen 
in acromegaly patients is extensive (Pivonello et  al. 
2017). The actual contribution of the different major 
classes of comorbidity to disease burden and death in 
acromegaly is not clear. Traditionally, cardiovascular 
disease, respiratory disease and cancer have been the 
main causes of increased mortality in acromegaly. With 
respect to cardiovascular and metabolic risk factors in the 
current cohort, we confirm that diabetes is a common 
problem in acromegaly, affecting more than a quarter 
of patients at diagnosis, in keeping with other studies 
(Hannon et  al. 2017). Hypertension was also frequent, 
being present in about 29% at diagnosis. Structural heart 
disease is an important component of acromegaly, and 
already 15.5% of patients had hypertrophy at diagnosis. 
We noted that sleep apnea syndrome, a classical 
acromegaly feature, that itself has a negative impact 
on cardiorespiratory morbidity is seen in a quarter of 
acromegaly patients at diagnosis. This figure is likely to 
be an underestimate, as with strict polysomnography, the 
rate of obstructive sleep apnea syndrome in acromegaly 
can be as high as nearly 70% (Attal & Chanson 2010). 
Acromegaly patients are not screened uniformly at 
diagnosis for sleep apnea or other associated problems, 
so the true prevalence rates of different comorbidities are 
uncertain. An important factor to consider is the effect 
of age on cardiovascular comorbidities, as we noted 
that patients with hypertension, cardiac hypertrophy 
and heart failure at diagnosis were significantly older at 
diagnosis (6–13 years) than those without cardiovascular 
complications. This raises the question as to what role 
acromegaly plays in the cardiovascular health of the aging 
patient? This is particularly of relevance as the current 
study has shown that more aged patients with acromegaly 
are being diagnosed. In this situation, it becomes difficult 
to attribute a causative role for GH hypersecretion to 
cardiac morbidities in acromegaly, and as patients age, the 
presence of acromegaly may simply represent one of the 
many contributory risk factors.
In the case of colonoscopy that is recommended for 
surveillance of acromegaly patients, this was performed in 
820 patients at diagnosis. While incomplete with respect 
to the total cohort size, it is still one of the largest datasets 
on colonic findings at diagnosis in acromegaly; 13% 
of patients had polyps but only four cases of colorectal 
cancer were already present at diagnosis. Indeed, the rate 
of recorded cancer cases either overall or by specific types 
(e.g. breast cancer in women) does not appear as being 
markedly elevated in the LAS Database patients in relation 
to general European populations (Lutz et  al. 2003). The 
prevalence of thyroid nodules was high in acromegaly at 
diagnosis; and 11 cases of thyroid cancer were identified 
at that time. The prevalence of thyroid nodules was 
probably an underestimation as ultrasound examinations 
were not performed routinely at diagnosis of acromegaly. 
There were some interesting findings regarding emerging 
comorbidities. Red blood cell count and hemoglobin 
concentrations were also raised in acromegaly, and 
we confirmed that these increased with IGF-1 levels 
but not GH. Again, this suggests that IGF-1 levels may 
be a better representation of the activity of acromegaly 
overall. The role of excessive GH-IGF-1 hypersecretion on 
erythropoiesis in acromegaly is a recognized but relatively 
neglected subject (Grellier et  al. 1996, Teramoto  & 
Ouchi 1997, Zoppoli et  al. 2011); however, in pediatric 
and adult GH deficiency, it is well established that GH 
replacement can lead to increased red blood cell measure 
and correction of anemia (Christ et  al. 1997, Valerio 
et al. 1997, Bergamaschi et al. 2006, Esposito et al. 2016). 
The role of increased red cell counts and potentially 
other hematological measures in relation to respiratory 
pathology (e.g. sleep apnea syndrome), cardiovascular 
disease and outcomes is a potentially valuable avenue of 
future research.
The LAS Database is the first international relational 
database used to study acromegaly following a standard 
methodological design. This first report of >3100 enrolled 
patients at diagnosis shows that the clinical and hormonal 
characteristics of acromegaly are evolving over time. While 
acromegaly affects slightly more females than males, 
female patients have a significantly longer delay before 
diagnosis; this may be due in part to males having larger 
tumors than females and these occur at a younger age. 
The age at first symptoms and at diagnosis of acromegaly 
is rising over time, indicating that improvements in 
diagnostic measures are detecting a greater proportion 
of older patients. In keeping with this, the LAS Database 
cohort also shows a triangular relationship between age, 
tumor size and GH secretion, with older patients having 
smaller tumors and lower GH secretion. Cardiometabolic 
comorbidities of acromegaly were frequently present at 
diagnosis, such as diabetes mellitus (29.6%), hypertension 
(28.8%), while cardiac hypertrophy was seen in 15.5%. 
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Thyroid nodules (34.0%), sleep apnea syndrome (25.5%) 
and colonic polyps (13%) were also frequent but detailed 
specific screening for these was less consistent at diagnosis. 
The LAS Database provides a standardized platform 
for combining large datasets across multiple centers 
internationally and forthcoming analyses will address 
important aspects of treatment responses and outcomes in 
acromegaly.
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